COMMUNIQUÉS West-GlobeNewswire

Quinze étudiants atteints d’une MII reçoivent des bourses pour poursuivre leurs études
17/09/2026
Le programme de bourses d’études MII d’AbbVie souligne 15 ans de reconnaissance de la résilience et des ambitions des étudiants qui vivent avec la maladie de Crohn ou la colite ulcéreuse à travers le Canada TORONTO, 17 [...]
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
17/09/2026
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
17/09/2026
New Filing Seeks Broad Protection Around Creative Medical’s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency, Manufacturing Controls and Additional Therapeutic Applications PHOENIX, [...]
Wandercraft Launches Eve™, the World’s First Self-Balancing Personal Exoskeleton, Bringing Hands-Free Upright Mobility to the Home
17/09/2026
FDA-cleared Eve is now commercially available in the U.S. to eligible adults with spinal cord injuries at any level, supported by a growing network for evaluation, training, reimbursement, delivery, and service NEW YORK [...]
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
17/09/2026
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma KANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a [...]
Recludix Pharma to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
17/09/2026
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
First Insight Corporation Launches The Focal Point Podcast
17/09/2026
Monthly conversations on where AI is changing healthcare, where it falls short, and what responsible innovation looks like PORTLAND, Ore., Sept. 17, 2026 (GLOBE NEWSWIRE) -- First Insight Corporation launched The Focal [...]
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
17/09/2026
Appointment supports Aerska's progression of its antibody-oligo conjugate platform and growing pipeline of RNA therapeutics for CNS disease Laura brings decades of leadership in developing complex genetic medicines from [...]
Matisse Pharmaceuticals closed Series A financing round to advance isupartob sodium through phase 2 clinical development
17/09/2026
Geleen, September 17, 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing isupartob sodium for the treatment of sepsis, today announced the successful completion of its Series A financing round. The € [...]
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
17/09/2026
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare [...]
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
17/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
17/09/2026
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil
17/09/2026
LockeT Has Expanded to Six Hospitals in Brazil Since Its August Launch Company Engages Experienced Cardiology Group to Support Expansion Across Argentina, Chile, Colombia and Additional Latin American Markets FORT MILL [...]
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
17/09/2026
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred [...]
Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine
17/09/2026
– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country [...]
Applied Biologics Receives Service-Disabled Veteran-Owned Small Business Certification
17/09/2026
Federal certification recognizes veteran ownership and strengthens Company’s ability to expand partnerships across federal healthcare and government markets SCOTTSDALE, Ariz., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Applied [...]
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
17/09/2026
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins Vancouver, Canada, Sept. 17, 2026 (GLOBE [...]
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
17/09/2026
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq: KALA) ("KALA" or the "Company") today [...]
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
17/09/2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had [...]

Pages